Page 1

IRADIMED 2 CORPORATION IRADIMED CORPORATION Announces Third Quarter 2021 Financial Results Reports third quarter 2021 revenue of $ 10.9 million , GAAP diluted EPS of $ 0.20 and non - GAAP diluted EPS of $ 0.23 ● Increases full - year 2021 financial guidance ● TIO Winter Springs , Florida , October 29 , 2021 - IRADIMED CORPORATION ( the " Company " ) ( NASDAQ : IRMD ) , a leader in the development of innovative magnetic resonance imaging ( " MRI " ) medical devices and the only known provider of a non - magnetic intravenous ( “ IV ” ) infusion pump system , and non magnetic patient vital signs monitoring systems that are designed for use during MRI procedures , today announced financial results for the three and nine months ended September 30 , 2021 . " I am pleased with these financial results and continue to be proud of our performance and resiliency in an everchanging environment marked by the continued uncertainties of COVID . With these financial results , we are on pace to post approximately 8 percent revenue growth over the pre - COVID 2019 year as well as achieve the highest full - year revenue in Iradimed's history , " said Roger Susi , President and Chief Executive Officer of the Company . Three Months Ended September 30 , 2021 For the third quarter ended September 30 , 2021 , the Company reported revenue of $ 10.9 million compared to $ 7.7 million for the third quarter 2020. Net income was $ 2.6 million , or $ 0.20 per diluted share , compared to $ 1.1 million , or $ 0.09 per diluted share for the third quarter 2020. The increase in net income and diluted earnings per share is primarily the result of a $ 3.2 million increase in revenue for the third quarter 2021 . Non - GAAP net income was $ 2.8 million , or $ 0.23 per diluted share , for the quarter ended September 30 , 2021 , and excludes $ 0.3 million of stock compensation expense , net of tax expense . Non - GAAP net income for the quarter ended September 30 , 2020 was $ 1.4 million , or $ 0.11 per diluted share , and excludes $ 0.3 million of stock compensation expense , net of tax . Nine Months Ended September 30 , 2021 For the nine months ended September 30 , 2021 , the Company reported revenue of $ 29.9 million compared to $ 23.2 million for the same period in 2020. Net income was $ 5.4 million , or $ 0.43 per diluted share , compared to $ 0.7 million , or $ 0.06 per diluted share for the same period in 2020. The increase in net income and diluted earnings per share is primarily the result of a $ 6.8 million increase in revenue and a $ 2.8 million decrease in general and administrative expenses , partially offset by a $ 3.3 million increase in income tax expense for the nine months ended September 30 , 2021. During the nine months ended September 30 , 2020 , the Company recognized total general and administrative expense of $ 3.2 million related to our former CEO . Non - GAAP net income was $ 6.2 million , or $ 0.50 per diluted share , for the nine months ended September 30 , 2021 , and excludes $ 0.8 million of stock compensation expense , net of tax expense . Non